• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Irritable Bowel Syndrome - Pipeline Review, H2 2011 - Product Image

Irritable Bowel Syndrome - Pipeline Review, H2 2011

  • Published: September 2011
  • 134 pages
  • Global Markets Direct

Irritable Bowel Syndrome - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Irritable Bowel Syndrome - Pipeline Review, H2 2011', provides an overview of the Irritable Bowel Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Irritable Bowel Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome. 'Irritable Bowel Syndrome - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Irritable Bowel Syndrome.
- A review of the Irritable Bowel Syndrome products under development READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Irritable Bowel Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Irritable Bowel Syndrome
Irritable Bowel Syndrome Therapeutics under Development by Companies
Irritable Bowel Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Irritable Bowel Syndrome Therapeutics - Products under Development by Companies
Irritable Bowel Syndrome Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Irritable Bowel Syndrome Therapeutics Development
Abbott Laboratories
GlaxoSmithKline plc
Albany Molecular Research, Inc.
Astellas Pharma Inc.
Dong-A Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Salix Pharmaceuticals, Ltd.
Warner Chilcott Limited
Menarini Group
Shire Plc
AlbireoPharma
Callisto Pharmaceuticals, Inc.
Pharmos Corporation
Lexicon Pharmaceuticals, Inc.
ProMetic Life Sciences Inc.
New York Health Care, Inc.
Alba Therapeutics Corporation
Ironwood Pharmaceuticals, Inc.
Helsinn Healthcare S.A.
Respiratorius AB
Ocera Therapeutics, Inc.
Akebia Therapeutics, Inc.
Melior Discovery, Inc.
Rottapharm SpA
Tioga Pharmaceuticals, Inc.
Rose Pharma A/S
Giaconda Limited
Targacept, Inc.
Napo Pharmaceuticals, Inc.
Kemin Industries, Inc.
Ardelyx, Inc.
RaQualia Pharma Inc.
SK Bio-Pharmaceuticals
Irritable Bowel Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Irribow - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LX1031 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LIBS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
M0014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xifaxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
M0012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AST-120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-304 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR 2017 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ROSE-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bifantis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ibaconda - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DDP733 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DDP225 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TC-6499 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YKP-GI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Welchol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PBI-1737 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mu Delta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Itopride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lyrica - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DA-6886 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ST-1141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AKB-4924 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Apriso - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDX5791 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONO-2952 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MLR 1045 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LX1033 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irritable Bowel Syndrome Therapeutics – Drug Profile Updates
Irritable Bowel Syndrome Therapeutics - Discontinued Products
Irritable Bowel Syndrome - Featured News
Sep 06, 2011: Furiex Reports Positive Phase II Results For MuDelta In Diarrhea-Predominant Irritable Bowel Syndrome
Sep 06, 2011: Furiex Reports Positive Phase II Results For MuDelta In Treatment Of Diarrhea-Predominant Irritable Bowel Syndrome
Aug 10, 2011: Lexicon Announces Publication Of Results From Phase II Trial Of LX1031 In Patients With Irritable Bowel Syndrome In Journal Of Gastroenterology
Aug 09, 2011: Ironwood And Forest Announce Submission Of New Drug Application For Linaclotide To FDA
Jul 28, 2011: Lexicon’s LX1033 Successfully Completes Phase I Clinical Trial
Jul 24, 2011: Neurim Announces Positive Results From Phase I And Phase Ib Clinical Trials With Neu-P11
Jun 16, 2011: Tioga Pharmaceuticals Receives Key US Patent For Use Of Asimadoline To Treat D-IBS
Jun 01, 2011: Tioga Pharmaceuticals Receives FDA's Fast Track Designation For Asimadoline
May 04, 2011: Ironwood And Forest To Present Linaclotide Results From Phase III Trials In Patients With Irritable Bowel Syndrome With Constipation
May 01, 2011: Salix Reports Positive Phase III Results Of XIFAXAN In Irritable Bowel Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Irritable Bowel Syndrome, H2 2011
Products under Development for Irritable Bowel Syndrome – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Abbott Laboratories, H2 2011
GlaxoSmithKline plc, H2 2011
Albany Molecular Research, Inc., H2 2011
Astellas Pharma Inc., H2 2011
Dong-A Pharmaceutical Co., Ltd., H2 2011
Ono Pharmaceutical Co., Ltd., H2 2011
Pfizer Inc., H2 2011
Salix Pharmaceuticals, Ltd., H2 2011
Warner Chilcott Limited, H2 2011
Menarini Group, H2 2011
Shire Plc, H2 2011
AlbireoPharma, H2 2011
Callisto Pharmaceuticals, Inc., H2 2011
Pharmos Corporation, H2 2011
Lexicon Pharmaceuticals, Inc., H2 2011
ProMetic Life Sciences Inc., H2 2011
New York Health Care, Inc., H2 2011
Alba Therapeutics Corporation, H2 2011
Ironwood Pharmaceuticals, Inc., H2 2011
Helsinn Healthcare S.A., H2 2011
Respiratorius AB, H2 2011
Ocera Therapeutics, Inc., H2 2011
Akebia Therapeutics, Inc., H2 2011
Melior Discovery, Inc., H2 2011
Rottapharm SpA, H2 2011
Tioga Pharmaceuticals, Inc., H2 2011
Rose Pharma A/S, H2 2011
Giaconda Limited, H2 2011
Targacept, Inc., H2 2011
Napo Pharmaceuticals, Inc., H2 2011
Kemin Industries, Inc., H2 2011
Ardelyx, Inc., H2 2011
RaQualia Pharma Inc., H2 2011
SK Bio-Pharmaceuticals, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Irritable Bowel Syndrome Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Irritable Bowel Syndrome, H2 2011
Products under Development for Irritable Bowel Syndrome – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos